Hims Falls as FDA Posts Warning Letter on Semaglutide Claims (1)

(Adds analyst commentary.)

Hims & Hers Health shares dropped to a session low, sliding as much as 9.8% after the FDA sent a warning letter to the telehealth platform, saying the company’s claims about compounded semaglutide products on their website are false or misleading.

• NOTE: HIMS opened lower, but it touched session low after this news
• “While HIMS will still be able to sell its compounded semaglutide, clearly the regulatory zeitgeist has shifted, and we think HIMS’ marketing campaigns will be under intense scrutiny, which will likely increase CACs,” writes Citi (sell) analyst Daniel Grosslight
  • Notes HIMS told Citi on ...